Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 4, 1998

View Archived Issues

Entropin concentrates its efforts on bringing Esterom to market

Inflazyme advances development of asthma therapeutic

Idec Pharmaceuticals: Q3 1998 highlights

Amylin: Q3 1998 highlights

Optimal dosing regimen for 5G1.1-SC in heart attack under evaluation in phase I trial

Connetics: Q3 1998 highlights

Novel isoquinoline anticonvulsants in development at SB

Korean laboratory prepares new series of TNF-alpha inhibitors

Meiji Seika discloses new neuroprotective substance isolated from fungus

Potent and selective COX-2 inhibitors from Merck Frosst useful for inflammation

New immunosuppressants in the pipeline at Kyowa Hakko

Otsuka NO inhibitor series particularly useful in asthma and atopic dermatitis

Schering-Plough describes SAR leading to discovery of potent cholesterol absorption inhibitor

Preclinical study results explain why TMK-688 does not induce drowsiness

Banyu seeks licensees for new parenteral carbapenems

Potential new antithrombotic agent profiled, structure revealed

GlyT-1 technology forms the basis of Allelix and Janssen neuropsychiatric collaboration

First Neoral equivalent cleared by FDA

New agreement between Pharmacopeia and Schering-Plough expands R&D collaboration

European research group focuses on TTD non-nucleoside reverse transcriptase inhibitors

Adoptive immunotherapy of cancer with HSPs covered by U.S. patent

Alza focuses on urology products; licenses Urispas

Medtronic seeks to become leader in neurological and spinal medical technologies

GenVec receives expanded patent coverage in field of gene therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...